The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial.A retrospective cohort design was used to determine if intensive chemoradiotherapy with purged autologous bone marrow rescue (ABMT) and/or 13-cis-retinoic acid (13-cis-RA) improved outcome for patients with high-risk neuroblastoma that was not metastatic to distant sites. We identified 72 patients with INSS Stage 3 neuroblastoma enrolled between 1991 and 1996 on the Phase 3 CCG-3891 randomized trial. Patients were analyzed on an intent-to-treat basis using a log-rank test.The 5-year event-free survival (EFS) and overall survival (OS) rates for patients with Stage 3 neuroblastoma were 55 +/- 6

作者：Julie R, Park；Judith G, Villablanca；Wendy B, London；Robert B, Gerbing；Daphne, Haas-Kogan；E Stanton, Adkins；Edward F, Attiyeh；John M, Maris；Robert C, Seeger；C Patrick, Reynolds；Katherine K, Matthay

来源：Pediatric blood & cancer 2009 年 52卷 1期